ARCH Venture Management as of March 31, 2026
Portfolio Holdings for ARCH Venture Management
ARCH Venture Management holds 10 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Maze Therapeatics (MAZE) | 18.2 | $123M | 4.1M | 29.85 | |
| Rapport Therapeutics (RAPP) | 17.2 | $117M | 3.7M | 31.29 | |
| Vir Biotechnology (VIR) | 17.1 | $116M | 13M | 8.96 | |
| Erasca (ERAS) | 16.9 | $115M | 7.1M | 16.18 | |
| Beam Therapeutics (BEAM) | 16.0 | $108M | 4.5M | 23.83 | |
| Lyell Immunopharma Com New (LYEL) | 9.6 | $65M | 3.2M | 20.06 | |
| Generate Biomedicines Com Shs | 3.6 | $24M | 1.9M | 12.50 | |
| 10x Genomics Cl A Com (TXG) | 0.7 | $4.6M | 218k | 21.23 | |
| Gossamer Bio (GOSS) | 0.4 | $2.6M | 8.1M | 0.33 | |
| Q32 Bio (QTTB) | 0.3 | $2.1M | 321k | 6.42 |
